[go: up one dir, main page]

CA2253869A1 - Acides oxobutyriques substitues agissant comme inhibiteurs des metalloproteinases matricielles - Google Patents

Acides oxobutyriques substitues agissant comme inhibiteurs des metalloproteinases matricielles

Info

Publication number
CA2253869A1
CA2253869A1 CA002253869A CA2253869A CA2253869A1 CA 2253869 A1 CA2253869 A1 CA 2253869A1 CA 002253869 A CA002253869 A CA 002253869A CA 2253869 A CA2253869 A CA 2253869A CA 2253869 A1 CA2253869 A1 CA 2253869A1
Authority
CA
Canada
Prior art keywords
substituted
matrix metalloprotease
metalloprotease inhibitors
carbons
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002253869A
Other languages
English (en)
Other versions
CA2253869C (fr
Inventor
Brian R. Dixon
Jinshan Chen
Michael Van Zandt
David R. Brittelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2253869A1 publication Critical patent/CA2253869A1/fr
Application granted granted Critical
Publication of CA2253869C publication Critical patent/CA2253869C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002253869A 1996-05-15 1997-05-12 Acides oxobutyriques substitues agissant comme inhibiteurs des metalloproteinases matricielles Expired - Fee Related CA2253869C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64838496A 1996-05-15 1996-05-15
US08/648,384 1996-05-15
PCT/US1997/007975 WO1997043238A1 (fr) 1996-05-15 1997-05-12 Acides oxobutyriques substitues agissant comme inhibiteurs des metalloproteinases matricielles

Publications (2)

Publication Number Publication Date
CA2253869A1 true CA2253869A1 (fr) 1997-11-20
CA2253869C CA2253869C (fr) 2003-04-22

Family

ID=24600568

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002253869A Expired - Fee Related CA2253869C (fr) 1996-05-15 1997-05-12 Acides oxobutyriques substitues agissant comme inhibiteurs des metalloproteinases matricielles

Country Status (18)

Country Link
EP (1) EP0912487A1 (fr)
JP (1) JP3417951B2 (fr)
CN (1) CN1163466C (fr)
AR (1) AR007096A1 (fr)
AU (1) AU727648B2 (fr)
CA (1) CA2253869C (fr)
CO (1) CO4990925A1 (fr)
HR (1) HRP970246B1 (fr)
ID (1) ID20291A (fr)
MY (1) MY132470A (fr)
PA (1) PA8429401A1 (fr)
PE (1) PE65998A1 (fr)
SV (1) SV1997000034A (fr)
TN (1) TNSN97085A1 (fr)
TW (1) TW467892B (fr)
WO (1) WO1997043238A1 (fr)
YU (1) YU18797A (fr)
ZA (1) ZA974032B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
JP5263548B2 (ja) * 2007-08-15 2013-08-14 杏林製薬株式会社 イブジラストを有効成分とする脳動脈瘤の予防、形成抑制又は治療剤
EP3126358A1 (fr) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 pour traiter des maladies des voies respiratoires
WO2015150363A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation
CA2944617A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Derives chiraux d'acide cyclopentanecarboxylique a disubstitution 2,5 et leur utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT74511A (en) * 1994-01-22 1997-01-28 British Biotech Pharm Metalloproteinase inhibitors, pharmaceutical compns. contg. them and process to prepare the said compds.
NZ323329A (en) 1995-12-22 1999-02-25 Warner Lambert Co 4-phenyl-piperidin-1-yl butyric acid derivatives and medicaments
HRP970242A2 (en) 1996-05-15 1998-04-30 Bayer Ag Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids

Also Published As

Publication number Publication date
AR007096A1 (es) 1999-10-13
EP0912487A1 (fr) 1999-05-06
WO1997043238A1 (fr) 1997-11-20
ZA974032B (en) 1998-02-19
JPH11509870A (ja) 1999-08-31
HRP970246A2 (en) 1998-04-30
CN1163466C (zh) 2004-08-25
HRP970246B1 (en) 2002-04-30
CN1225622A (zh) 1999-08-11
CA2253869C (fr) 2003-04-22
ID20291A (id) 1998-11-19
AU727648B2 (en) 2000-12-21
TNSN97085A1 (fr) 2005-03-15
JP3417951B2 (ja) 2003-06-16
MY132470A (en) 2007-10-31
TW467892B (en) 2001-12-11
AU3121997A (en) 1997-12-05
SV1997000034A (es) 1999-07-05
YU18797A (en) 1999-11-22
CO4990925A1 (es) 2000-12-26
PA8429401A1 (es) 2000-05-24
PE65998A1 (es) 1998-10-20

Similar Documents

Publication Publication Date Title
CA2032904A1 (fr) Agents bloquants de l'effet edrf et formulation pour le traitement de l'etat de choc
DE69512797D1 (en) Prostaglandin-synthase hemmer
GR3035181T3 (en) Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
EA200100867A1 (ru) Сульфаматогидроксамовая кислота как ингибитор металлопротеаз
CA2264254A1 (fr) Amides d'acide phosphinique utilises comme inhibiteurs de metalloproteases de matrices
BR9713417A (pt) Composto de açúcar, agente gelificante, composição de agente gelificante, processos para suas preparações e composição de gel.
CA2085555A1 (fr) Doubles inhibiteurs de la no synthase et de la cyclo-oxygenase, leur mode de preparation et preparations pharmaceutiques qui les contiennent
CA2153979A1 (fr) Composes presentant une puissante activite d'antagonistes du calcium et d'antioxydants et leur utilisation en tant qu'agents cytoprotecteurs
JPS5671074A (en) 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
DK1007039T3 (da) Hidtil ukendte heterocykliske analoger til diphenylethylenforbindelser
CA2279088A1 (fr) Composition fongicide et methode pour l'utilisation de ladite composition
KR840000236A (ko) 포유류의 국부용 제형의 수분 손실량을 극소화시키는 방법
ATE271614T1 (de) Quinone-derivate zur verbesserung der zellulare bioenergie
KR900011754A (ko) (디-3급-부틸히드록시페닐)티오 유도체
KR890013009A (ko) 2'-데옥시-5-플루오로우리딘 유도체
ES8105351A1 (es) Procedimiento de obtencion de composiciones termo-estabili- zadoras de resinas
EA200201223A1 (ru) Тиенодибензоазуленовые соединения в качестве ингибиторов фактора некроза опухоли
KR940703655A (ko) 약제학적 조성물과 그 제조방법
CA2253869A1 (fr) Acides oxobutyriques substitues agissant comme inhibiteurs des metalloproteinases matricielles
KR920703512A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
CA2099867A1 (fr) Utilisation de 4,6-di-tert-butyl-5-hydroxy-1,3-pyrimidines substituees en 2 comme agents anti-inflammatoires
ES8105352A1 (es) Procedimiento de obtencion de composiciones termo-estabili- zadoras de resinas
ATE266641T1 (de) Picolinsäure-derivate zur behandlung von il-1 und tnf bedingten erkrankungen
KR950702554A (ko) 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents)
EP0135189A3 (fr) Malonamides à utilisation pharmaceutique

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed